Developments in the design and therapeutic applications of GSK3β inhibitors.

Glycogen synthase kinase-3β (GSK3β) has emerged as one of the most thoroughly validated therapeutic targets in modern drug discovery, with dysregulation implicated in neurodegenerative diseases, metabolic disorders, cancer, psychiatric conditions, and inflammatory pathologies. This review provides a comprehensive and critical overview of recent advances in GSK3β inhibitor design, encompassing ATP-competitive compounds, non-ATP-competitive modulators, covalent inhibitors, and targeted protein degradation strategies. We integrate computational approaches-including pharmacophore modeling, molecular dynamics simulations, and emerging artificial intelligence methods-with experimental validation, distinguishing this work from prior reviews. Therapeutic applications across Alzheimer's disease, type 2 diabetes, cancer, bipolar disorder, and inflammatory conditions are critically examined, with particular emphasis on clinical trial outcomes and translational challenges. We analyze why clinical translation has lagged, identifying insufficient CNS penetration, inadequate target engagement validation, and suboptimal patient selection as key factors, and provide recommendations for future development. Emerging directions including isoform-selective inhibition, context-dependent modulation, combination therapies, and biomarker-driven strategies are discussed. This review offers an integrated perspective on the GSK3β inhibitor landscape and outlines actionable opportunities for developing next-generation therapeutics. GSK3β is a protein that acts like a molecular “control switch” inside our cells. It helps regulate many vital processes, including memory formation, blood sugar control, cell survival, and inflammation. When this switch is not properly regulated, it can contribute to diseases such as Alzheimer’s disease, diabetes, cancer, and mood disorders.Researchers around the world are working to develop medicines that can fine-tune GSK3β activity. In this article, we summarize how these efforts have progressed. We explain how scientists use computer modeling together with laboratory experiments to design and optimize new drug candidates. We also describe the main challenges in developing GSK3β-targeting medicines, such as ensuring that the drugs reach the right tissues (especially the brain), act specifically on GSK3β rather than other kinases, and do not cause serious side effects.Some experimental drugs that inhibit GSK3β have shown promising results in animal models and early clinical studies, but none have yet been approved for routine clinical use. We highlight several new strategies that may yield more effective treatments in the future, offering cautious optimism for patients affected by these difficult-to-treat diseases.